Plain-English translation of NCT06880523 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of three medications—, tremelimumab, and —to treat advanced liver cancer that cannot be removed by surgery. Half of the participants will receive all three medications together, while the other half will receive just the first two. The goal is to see whether adding the third drug helps people live longer and keeps their cancer from growing.
Earlier research showed that each of these medications can help slow or shrink liver cancer on its own. This trial wants to find out whether using all three together works even better than using just two, which could offer patients a more effective treatment option.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the three-medication combination or the two-medication combination. You will attend regular clinic visits to receive your treatment and have blood tests and imaging scans (CT or MRI) to monitor how your cancer responds. The study will track how long you live and how well the treatment controls your cancer, as well as any side effects you experience. Your participation will continue until your cancer progresses, you experience unacceptable side effects, or the study ends.
AI-generated summary from trial data · Jul 22, 2026 · Not medical advice
Canada